- China Pacific has seen significant growth in prelim net income, increasing by 60% to 70% over the first nine months of the year.
- The prelim net income is estimated to be between 37 billion yuan and 39.4 billion yuan.
- Investor sentiment towards China Pacific is generally positive, with 21 analyst recommendations to buy the stock.
- There are 4 hold recommendations for China Pacific, indicating some investors believe the company’s stock is currently fairly valued.
- No analysts have recommended selling the stock, suggesting a strong confidence in China Pacific’s performance.
A look at China Pacific Insurance (Group) Co., Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
China Pacific Insurance (Group) Company, Ltd. is viewed positively for its long-term outlook according to Smartkarma Smart Scores. Based on the scores of Value 4, Dividend 4, Growth 4, Resilience 3, and Momentum 5, the company is deemed to have a promising future. With high ratings in factors such as dividend and growth, investors may see potential in China Pacific Insurance as a reliable investment option. Moreover, the strong momentum score indicates that the company is currently performing well, which could bode well for its future prospects.
As an integrated insurance services provider, China Pacific Insurance (Group) Company, Ltd. offers life and property insurance products through its subsidiaries. The favorable Smart Scores suggest that the company is well-positioned for future growth and stability within the insurance industry. Investors looking for a combination of value, growth, dividends, and momentum may find China Pacific Insurance to be an attractive long-term investment opportunity.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
